stockrow
Friday 6 November 2026
Export COGT’s income statement to Excel — free account
Cogent Biosciences, Inc.
COGT Healthcare Biotechnology
- EPS
- +1.89%
- Free cash flow
- −42.0%
Quarter to June 2026, against a year earlier
31.60
2.02
+6.83%
Follow COGT
Alert me
Cogent Biosciences, Inc. (COGT) Gross margin
Cogent Biosciences, Inc.'s gross margin over the twelve months to 30 September 2023 was 0.00%, down 0.0 percentage points from fiscal 2022 (0.00%). Over the past ten years it has ranged from 0.00% (fiscal 2022) to 100.0% (fiscal 2020) — the current reading is the lowest in ten years. That is below the Biotechnology industry median of 68.5% and below the Healthcare sector median of 54.5%.
Gross margin, annual
Embed this chart
Annual newest first
| Period | Gross margin | Change (points) |
|---|---|---|
| FY2022 | 0.00% | 0.00 |
| FY2021 | 0.00% | (100.00) |
| FY2020 | 100.0% | 0.00 |
| FY2019 | 100.0% | 0.00 |
| FY2018 | 100.0% | 0.00 |
| FY2017 | 100.0% | 0.00 |
| FY2016 | 100.0% | 0.00 |
| FY2015 | 100.0% | — |
Quarterly newest first
| Period | Gross margin | Change (points) |
|---|---|---|
| Sep 2023 | 0.00% | 0.00 |
| Jun 2023 | 0.00% | 0.00 |
| Mar 2023 | 0.00% | 0.00 |
| Dec 2022 | 0.00% | 0.00 |
| 23 more quarters | Free account |
Against its own ten years
Low 0.00%
High 100.0%
Ten-year median
100.0%
Current reading's percentile
25
Gross margin against peers
| Company | Gross margin |
|---|---|
| CRSP CRISPR Therapeutics AG compare | 100.0% |
| DNTH Dianthus Therapeutics, Inc. compare | 100.0% |
| TVTX Travere Therapeutics, Inc. compare | 98.5% |
| PTCT PTC Therapeutics, Inc. compare | 93.2% |
| KOD Kodiak Sciences Inc. compare | 0.00% |
| COGT Cogent Biosciences, Inc. | 0.00% |
| SRRK Scholar Rock Holding Corporation compare | 0.00% |
| ERAS Erasca, Inc. compare | 0.00% |
| MANE Veradermics Incorporated compare | — |
| Biotechnology industry median | 68.5% |
| Healthcare sector median | 54.5% |
| Market median | 46.0% |
What Gross margin is
Gross Margin tells an investor how much of each sale a company keeps after paying the direct costs of making or buying what it sells.
Gross Profit ÷ Revenue
More on COGT
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- The full statement